White, Annesha; Odedina, Folakemi; Xiao, Hong; … - In: Disease Management and Health Outcomes 14 (2006) 2, pp. 99-106
Background: Hyperphosphatemia is very common in patients with end-stage renal disease (ESRD). Recently, a new phosphate binder, sevelamer, has become available in the US to treat this condition. The high cost of sevelamer has significantly impacted on third-party payors such as Florida Medicaid....